PPARG and fatty liver disease: In addition, a recent study reported that lobeglitazone attenuated hepatic steatosis through the inhibition of PPARγ phosphorylation in chronic obese mice (17); however, underlying mechanism of the effects of lobeglitazone in NAFLD is still unclear.